Positive Tedopi combination data in OC

OSE Immunotherapeutics has announced positive topline results for the Phase II TEDOVA trial, which assesses lead asset Tedopi in combination with pembrolizumab in patients with platinum-sensitive recurrent ovarian cancer (OC). Encouragingly, the primary endpoint of progression-free survival (PFS) was met with statistical significance, comparing Tedopi plus pembrolizumab to best supportive care. There was also a 28% reduction in risk of progression or death with Tedopi plus pembrolizumab, compared to Tedopi. Collectively, the outcomes represent the first positive trial in platinum sensitive OC in several years, and are an encouraging development for OSE, in our view, offering scope for the broader clinical utility of OSE’s lead asset (bey...